News
Effect of Empagliflozin on Clinical Stability in Patients with Heart Failure and Reduced LV Ejection Fraction
Previous studies have shown that the oral antidiabetic drug empagliflozin reduces the risk of death from cardiovascular causes or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetic and non-diabetic patients. The aim of the EMPEROR-Reduced clinical study was to supplement data on the effect of empagliflozin on the incidence of heart failure worsening events requiring hospitalization or outpatient treatment.
Overlap of SGLT2 Inhibitors from Diabetology to Cardiology
As recent research shows, one of the modern groups of antidiabetic drugs - SGLT2 inhibitors, also…
Heart Failure in the Light of New ESC Guidelines
Dear Doctor, The Czech Society of Internal Medicine of ČLS JEP invites you to watch the symposium,…
Heart Failure in Light of New ESC Guidelines
Dear Doctor, The Czech Society of Internal Medicine ČLS JEP invites you to watch the symposium,…
Early Intervention in the Early Phase of Psychosis
A meta-analysis of 10 randomized studies examined whether early intervention in the initial phase…
Association between Cardiovascular Risk Factors and Cognitive Disorders in Patients with Schizophrenia
Schizophrenia is a disease characterized by a certain degree of cognitive impairment, but also an…
How Do Sleep and Depression Influence Each Other?
It is known that most patients with depression encounter some form of sleep disorder. In the…
Conditions for the Use of Mucolytics in Children Are Tightening in Europe − Which Treatment Is Preferred?
There has been a long-standing discussion among experts regarding the benefits of individual…
Optimization of Romiplostim Administration in ITP Treatment
In their newly published review article, authors from several American institutions summarize…
Fatigue as a Significant Symptom of Immune Thrombocytopenia from the Patients' Perspective
The I-WISh survey assessed the impact of immune thrombocytopenia (ITP) and its treatment on…